Spark Therapeutics, Inc. (NASDAQ:ONCE) was upgraded by equities research analysts at Chardan Capital from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage presently has a $100.00 target price on the biotechnology company’s stock, up from their prior target price of $60.00. Chardan Capital’s price target would indicate a potential upside of 26.94% from the stock’s previous close.

A number of other research firms also recently weighed in on ONCE. UBS AG reaffirmed a “buy” rating and set a $92.00 price target (up previously from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Zacks Investment Research downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Stifel Nicolaus reaffirmed a “buy” rating and set a $92.00 price target (up previously from $77.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $95.00 price target (up previously from $85.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $82.27.

Spark Therapeutics (ONCE) traded up 0.19% during mid-day trading on Tuesday, reaching $78.78. 823,813 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $64.99 and a 200 day moving average price of $59.11. The company’s market cap is $2.44 billion. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $80.89.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. During the same period last year, the company earned ($1.04) EPS. The company’s revenue was up 14.7% compared to the same quarter last year. Equities analysts predict that Spark Therapeutics will post ($7.35) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. (ONCE) Raised to Buy at Chardan Capital” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/spark-therapeutics-inc-once-raised-to-buy-at-chardan-capital.html.

In other Spark Therapeutics news, Director Anand Mehra sold 211,858 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $70.15, for a total transaction of $14,861,838.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Barge Joseph La sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $55.00, for a total value of $275,000.00. Following the sale, the general counsel now directly owns 9,567 shares of the company’s stock, valued at approximately $526,185. The disclosure for this sale can be found here. In the last three months, insiders sold 314,310 shares of company stock valued at $21,866,838. 7.30% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Spark Therapeutics by 0.9% in the first quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock valued at $248,386,000 after buying an additional 40,698 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 4,875 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Spark Therapeutics by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 185,036 shares of the biotechnology company’s stock valued at $9,233,000 after buying an additional 10,616 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Spark Therapeutics by 10.1% in the first quarter. Tocqueville Asset Management L.P. now owns 59,850 shares of the biotechnology company’s stock valued at $3,192,000 after buying an additional 5,500 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Spark Therapeutics by 10.9% in the first quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock valued at $5,923,000 after buying an additional 10,916 shares in the last quarter. 88.95% of the stock is owned by institutional investors and hedge funds.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.